Bookmark
Forward
QuickView for zanamivir (compound)
PubChem
| Name: | Zanamivir |
|---|---|
| PubChem Compound ID: | 5271915 |
| Description: | A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE. |
| Molecular formula: | C11H18N4O8 |
| Molecular weight: | 334.283 g/mol |
| Synonyms: |
AIDS211235; D-Glycero-D-galacto-non-2-enonic acid, 4-[(aminoiminomethyl)amino]-2,6-anhydro-5-(carboxyamino)-3,4,5-trideoxy-; AIDS-211235; Zanamivir
|
DrugBank
Identification
| Name: | Zanamivir |
|---|---|
| Name (isomeric): | DB00558 |
| Drug Type: | small molecule |
| Description: | A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE. |
| Synonyms: |
Zanamavir; Modified sialic acid; GNA; GANA; ZMR
|
| Brand: | Relenza |
| Category: | Enzyme Inhibitors, Neuraminidase Inhibitors, Antiviral Agents |
| CAS number: | 139110-80-8 |
Pharmacology
| Indication: | For the prevention and treatment of influenza A and B. |
|---|---|
| Pharmacology: |
Zanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Zanamivir has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micro...
show more » |
| Mechanism of Action: | The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others. |
| Absorption: | Absolute bioavailability is very low following oral administration (2%). Following oral inhalation, bioavailability is 4% to 17%. |
| Protein binding: | Zanamivir has limited plasma protein binding (<10%). |
| Biotransformation: | Not metabolized |
| Route of elimination: | It is excreted unchanged in the urine with excretion of a single dose completed within 24 hours. Unabsorbed drug is excreted in the feces.Zanamivir is renally excreted as unchanged drug. |
| Half Life: | 2.5-5.1 hours |
| Clearance: | 2.5 - 10.9 L/h [Following oral inhalation 10 mg] 5.3 L/h [Normal renal function receiving IV single dose of 4 mg or 2 mg] 2.7 L/h [Patients with mild and moderate renal impairement receiving IV single dose of 4 mg or 2 mg] 0.8 L/h [Patients with severe renal impairement receiving IV single dose of 4 mg or 2 mg] |
| Affected organisms: | Influenza A virus||Influenza B virus |
Targets
